Biotech Movers

Bull’s Eye Report: Pharmacyclics (PCYC)

Biotech is a hot industry that's extremely volatile right now. Get on the right side of that volatility with Pharmacyclics (PCYC). More

Bulls vs. Bears: Can Biogen Keep Booming?

Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments. More

Biotech Movers: Acadia Jumps, Affymax Crashes

Last week, Acadia Pharmaceuticals rode the winds of good clinical results, while news of mass layoffs sent Affymax crashing again. More

Biotech Movers: Spectrum, AEterna Among Big Losers

A stopped phase 3 trial grounded AEterna Zentaris and a downshift in guidance kneecapped Spectrum Pharmaceuticals last week. More

Biotech Movers: Peregrine, PharmAthene Climb on Analyst Coverage

Last week in biotech news, Peregrine and PharmAthene both climbed on bullish analyst coverage. Also, find out why Sequenom shed double-digits in one day. More

Biotech Movers: Affymax Crashes on Recall

Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward. More

Biotech Movers: Chelsea Doubles, Vivus Dips

Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared. More

Biotech Movers: Big Bumps All Around

Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble. More

Biotech Movers: A Doubler for Opexa

A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers. More

Biotech Movers: Keryx Jumps, Sarepta Slips

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More